Results 111 to 120 of about 11,898 (160)

Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy: roles of underlying diseases and immunomodulatory therapies in FAERS. [PDF]

Front Immunol
Lin X, Qin N, He B, Chen J, Zhang Y, Wang H, Liu W.   +6 more
europepmc   +1 more source

Integrin β1 Demarks Precursors of Brain-Residing Antibody-Secreting Cells in Multiple Sclerosis. [PDF]

Neurol Neuroimmunol Neuroinflamm
Kuiper KL, Bogers L, Rip J, van Hasselt Y, Melief MJ, Wierenga-Wolf AF, Klein Kranenbarg RAM, Bindels E, van de Werken HJG, de Beukelaar J, Smets I, Wokke B, Smolders J, van Luijn MM.   +13 more
europepmc   +1 more source

Access, satisfaction, adherence and safety to subcutaneous natalizumab compared to intravenous natalizumab in multiple sclerosis in a real-life cohort: first report from Latin America. [PDF]

Ther Adv Neurol Disord
Silva BA, Santajuliana F, Casas M, Lázaro L, Pita C, Cohen L, Rinaldi G, Alonso R, Míguez J, D'Alessandro S.   +9 more
europepmc   +1 more source

Comparative evaluation of STRATIFY JCV™ and IMMUNOWELL™ assays for anti-JCV antibody detection in natalizumab-treated RRMS patients. [PDF]

Ther Adv Neurol Disord
Chisari CG, Spampinato G, Crimì P, Ferraro E, Lo Fermo S, Cimino V, Zappia M, Patti F.   +7 more
europepmc   +1 more source

Maternal Multiple Sclerosis and Offspring's Developmental and Behavioral Profile: A Case-control Study. [PDF]

Curr Neuropharmacol
Siracusano M, Landi D, Carloni E, Scoppola C, Ferrara M, Riccioni A, Arturi L, Gialloreti LE, Cicala M, Napoli F, Niolu C, Mazzone L, Marfia GA.   +12 more
europepmc   +1 more source

Kappa Free Light Chains Reflect Treatment Response and Progression Independent of Focal Inflammation in Multiple Sclerosis. [PDF]

Eur J Neurol
Rosenstein I, Axelsson M, Johnsson M, Malmeström C, Kvartsberg H, Zetterberg H, Lycke J, Novakova L.   +7 more
europepmc   +1 more source

Profiling the Cerebrospinal Fluid Proteome in Progressive Multiple Sclerosis: Treatment Effects and Associations with IgM Oligoclonal Bands. [PDF]

J Neuroimmune Pharmacol
El Mahdaoui S, Kosa P, Komori M, Veiga González JL, Chow HH, Ratzer R, Madsen CG, Siebner HR, Bielekova B, Villar LM, Romme Christensen J, Sellebjerg F.   +11 more
europepmc   +1 more source

Experimental Therapies in Multiple Sclerosis: Epstein-Barr Virus and Potential EBV-Related Therapeutic Strategies-A Systematic Review. [PDF]

J Clin Med
Bartczak J, Gronowski P, Małek M, Denkiewicz A, Grodzka O, Chądzyński P, Domitrz I.   +6 more
europepmc   +1 more source

Patient Preference and Time Allocation Associated with Transition from Intravenous to Subcutaneous Administration of Natalizumab (Tysabri) in Patients with Relapsing Remitting MS - A Questionnaire Study. [PDF]

Patient Prefer Adherence
Almroth A, Söderbärg K, Sjöblom I.
europepmc   +1 more source

Spectrum and signals of medication-associated cognitive disorder: a comprehensive disproportionality analysis with cross-database validation. [PDF]

Front Pharmacol
Wen H, Dong Y, Wang R.
europepmc   +1 more source